Follow-up of chronic lymphocytic leukemia (CLL) patients who relapse after autologous stem cell transplantation (ASCT)

被引：1
|
作者：
Trisolini, SM
Mauro, FR
Capria, S
Cimino, G
De Propris, MS
Proia, A
Foa, R
Meloni, G
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] Mil Hosp Celio, Rome, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.5212.5212
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5212
引用
收藏
页码：388B / 388B
页数：1
相关论文
共 50 条
  • [31] Long term outcome of autologous stem cell transplantation for chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL).
    Pavletic, Z
    Bierman, P
    Vose, J
    Bishop, M
    Wu, D
    Pierson, J
    Kollath, J
    Kessinger, A
    Armitage, J
    BLOOD, 1997, 90 (10) : 1032 - 1032
  • [32] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
    E Olavarria
    O G Ottmann
    M Deininger
    R E Clark
    G Bandini
    J Byrne
    J Lipton
    A Vitek
    M Michallet
    W Siegert
    A Ullmann
    B Wassmann
    D Niederwieser
    T Fischer
    Leukemia, 2003, 17 : 1707 - 1712
  • [33] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
    Olavarria, E
    Ottmann, OG
    Deininger, M
    Clark, RE
    Bandini, G
    Byrne, J
    Lipton, J
    Vitek, A
    Michallet, M
    Siegert, W
    Ullmann, A
    Wassmann, B
    Niederwieser, D
    Fischer, T
    LEUKEMIA, 2003, 17 (09) : 1707 - 1712
  • [34] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
    A Bacigalupo
    Leukemia, 2003, 17 : 1722 - 1722
  • [35] Quantitative PCR predicts early relapse in patients with chronic lymphocytic leukemia (CLL) submitted to autologous stem cell transplantation. The case for early clinical intervention.
    Moreno, C
    Villamor, N
    Colomer, D
    Esteve, J
    Bosch, F
    Lopez-Guillermo, A
    Campo, E
    Montserrat, E
    BLOOD, 2004, 104 (11) : 620A - 621A
  • [36] Allogeneic and autologous hematopoetic stem cell transplantation for chronic lymphocytic leukemia
    Kulkarni, S
    Powles, R
    Cunningham, D
    Sirohi, B
    Rudin, C
    Saso, R
    Treleaven, J
    Reiley, U
    Singhal, S
    Mehta, J
    Matutes, E
    Catovsky, D
    BONE MARROW TRANSPLANTATION, 2002, 29 : S165 - S165
  • [37] EFFICACY OF RESCUE IMMUNOTHERAPY AND SURVIVAL IN PATIENTS WITH HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAD CLINICAL RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
    Hahn, M.
    Dietrich, S.
    Herth, I.
    Hegenbart, U.
    Walter, E.
    Rieger, M.
    Stadtherr, P.
    Bondong, A.
    Ho, A. Dick
    Dreger, P.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S142 - S143
  • [38] Treatment-related MDS/AML after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): An EBMT survey.
    Dreger, P
    van Biezen, A
    Brukx, K
    Boogaerts, M
    Michallet, M
    Milligan, D
    Niederwieser, DW
    BLOOD, 2005, 106 (11) : 326A - 327A
  • [39] Allogeneic stem cell transplantation for chronic lymphocytic leukemia (B-CLL).
    Pavletic, ZS
    Bierman, PJ
    Tarantolo, SR
    Vose, JM
    Wu, D
    Reed, EC
    Pierson, JL
    Lynch, J
    Kessinger, A
    Armitage, JO
    Bishop, MR
    BLOOD, 1997, 90 (10) : 4508 - 4508
  • [40] CD38 expression has no prognostic influence after autologous stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL)
    Schloe, U
    Viehmann, K
    Lange, A
    Ritgen, M
    Dreger, P
    BONE MARROW TRANSPLANTATION, 2002, 29 : S165 - S165
12345